An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

Polycomb蛋白的进化保守功能可抑制MHC I类抗原呈递途径,从而使癌细胞逃避免疫攻击。

阅读:1
作者:Marian L Burr ,Christina E Sparbier ,Kah Lok Chan ,Yih-Chih Chan ,Ariena Kersbergen ,Enid Y N Lam ,Elizabeth Azidis-Yates ,Dane Vassiliadis ,Charles C Bell ,Omer Gilan ,Susan Jackson ,Lavinia Tan ,Stephen Q Wong ,Sebastian Hollizeck ,Ewa M Michalak ,Hannah V Siddle ,Michael T McCabe ,Rab K Prinjha ,Glen R Guerra ,Benjamin J Solomon ,Shahneen Sandhu ,Sarah-Jane Dawson ,Paul A Beavis ,Richard W Tothill ,Carleen Cullinane ,Paul J Lehner ,Kate D Sutherland ,Mark A Dawson

Abstract

Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2) that mediates coordinated transcriptional silencing of the MHC-I antigen processing pathway (MHC-I APP), promoting evasion of T cell-mediated immunity. MHC-I APP gene promoters in MHC-I low cancers harbor bivalent activating H3K4me3 and repressive H3K27me3 histone modifications, silencing basal MHC-I expression and restricting cytokine-induced upregulation. Bivalent chromatin at MHC-I APP genes is a normal developmental process active in embryonic stem cells and maintained during neural progenitor differentiation. This physiological MHC-I silencing highlights a conserved mechanism by which cancers arising from these primitive tissues exploit PRC2 activity to enable immune evasion.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。